HOUSTON--(BUSINESS WIRE)--Power3 Medical Products, Inc. (OTCBB: PWRM), announced today that it has concluded its initial research and has moved toward commercialization by continuing to validate and perfect its proprietary blood serum-based tests to diagnose Alzheimer’s disease. Power3 said these non-invasive tests, developed by using protein biomarkers it discovered, have shown greater than 90% sensitivity in identifying patients with Alzheimer’s disease, including patients that are pre-symptomatic.
